Market Research Blog

The global luciferase assays market is estimated to be valued around US$ 1.3 Billion in 2022, and is likely to surpass US$ 3 Billion by 2032. A bioluminescence experiment requires a paired set of biochemical: an enzyme named luciferase and a substrate, which is a molecule that emits light upon interacting with the enzyme or photoprotein. For each of the bioluminescent system required there is a unique co- factors and buffers that are required. Around us there are a lot of biological, natural and light producing systems which produces the enzyme named luciferases.

The substrate of luciferases is coin as luciferins. Emil Heinrich DuBois-Reymond, a German physiologist coined both these terms. Luciferases and luciferins are both involved in totally different reactions. For instance, the most commonly used luciferase detects the biological energy molecule adenosine triphosphate.

Luciferase Assays Market: Drivers and Restraints 

The market for luciferase assay is expected to upsurge owing to its penetrating usage in research to study the gene expression. Moreover, these luciferases has become powerful tool in molecular biology and genetic engineering where they have replaced chloramphenicol acetyltrans-ferase gene as a reporter. Bioluminescence is now filling its own niches as well as competing with chemiluminescence.

ATP detection via firefly luciferase, for example, has no chemiluminescent counterpart. There is tremendous technological development in the luciferase assay market where the current luciferase technologies permit the quantitative visualization of gene expression at single-cell resolution by imaging its luminescence in real-time using a highly sensitive charged-coupled device (CCD) camera.

Luciferase Assays Market: Segmentation 

On the basis of assay type the luciferase assays market can be segment as: 

• Beta-galactosidase (LacZ) assays
• Luciferase assays
• Fluorescent protein related assays
• Chloramphenicol acetyltransferase (CAT) assays

• Others

On the basis of application the luciferase assays market can be segment as: 

• Gene expression
• Post-translational modification
• Protein-protein interaction

• Metabolic activity
• Others

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-5565

Luciferase Assays Market: Overview 

These luciferases are used in bioluminescence assays as researchers believe that where there is light there would be ATP and measuring the light emitted while carrying out the bioluminescence assay is the measure of the metabolic activity. Today luciferases is used in all forms of testing to check the ATP. It is used to check the microbial contamination in many of the beverages company.

There are a number of studies going on where the researchers link the interest gene with the luciferases to study the metabolic activity. The investigator through this linkage is able to follow gene expression at different stages of development in a transgenic organism.

In terms of geography, luciferase assays market has been divided into seven regions including North- America, Eastern Europe, Western Europe, Asia- Pacific excluding Japan, Japan Middle-East & Africa and Latin America. North America is expected to remain the dominating region while Asia Pacific is expected to emerge as a fastest growing region.

Strong research funding and government to study newer assay methods makes North America the dominating region. Economically developing regions such as Asia Pacific has many companies focusing their resources in this region and trying to explore the luciferase assay market potential.

Luciferase Assays Market: Key Market Participants 

Some of the luciferase assays market participants are Life Technologies, Sigma Aldrich, Thermo Fisher, Promega, Clontech, Invivogen, Roche Applied Sciences, Switchgear Genomics, Origene, Perkin Elmer, EMD Millipore, Clontech, Gold Biotechnology, Lonza and GE Healthcare Life Sciences.

New product launch, collaborations and acquisitions are few of the strategies the luciferase assays market players undertake. For instance, Promega Corporation introduced a new product named Nano-Glo Dual-Luciferase Reporter (NanoDLR) Assay, a two-reporter system that incorporates NanoLuc luciferase technology, providing increased data quality and greater sensitivity for biologically complex applications.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on 

• Market Segments
• Market Dynamics

• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology

• Value Chain

Regional analysis includes 

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)

• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-5565

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Investment Feasibility Matrix

3.6. PESTLE and Porter’s Analysis

3.7. Regulatory Landscape

3.7.1. By Key Regions

3.7.2. By Key Countries

3.8. Regional Parent Market Outlook

4. Global Luciferase Assays Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-5565

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

As per Future Market Insights’ latest industry analysis, the global coronavirus immunoassay market was around US$ 3.7 Bn in 2021. Sales are projected to increase at a CAGR of 5.5% over the forecast period, with the market valuation reaching US$ 6.9 Bn in 2032.

COVID-19 has a wide range of clinical presentations, ranging from mild flu-like symptoms to life-threatening disorders, hence efficient testing during early stages of infection is critical for distinguishing COVID-19 patients from those with other illnesses.

Patients who are at a higher risk of having more significant COVID-19 symptoms can benefit from early diagnosis, which allows doctors to intervene quickly. More complex diagnostic testing based on viral genomic sequencing is critical for assessing the pace and degree of mutational variability associated with SARS-CoV-2, as well as finding new virus strains for more effective vaccine development.

“Increasing demand for reliable diagnostic tests and equipment, along with rising investments in the expansion of the healthcare infrastructure across emerging economies will augment the growth in the market,” says an FMI analyst.

Key Takeaways:

• Based on product type, sales in the immunoassay kits & reagents segment are forecast to increase at a 5.4% CAGR through 2032.
• In terms of assay type, the LFA assays segment will hold 45% of the total market share by 2032.
• By purpose, demand in the clinical use segment will increase at a 5.1% CAGR through 2032.
• Based on specimen type, Nasopharynx specimens are leading the market.
• Clinical diagnostics hold around 4% of the coronavirus immunoassay market, owing to the high volumes of the infected patient population, post the advent of the COVID-19 pandemic.
• Demand in the healthcare sector will grow at a 4.9% CAGR over the assessment period.

Competition Landscape

Key players operating in the coronavirus immunoassay market include Beckman Coulter, Thermo Fisher Scientific, DiaSorin, Shenzhen Bioeasy Biotechnology Co., Ltd. and others. With several key players with established presence existing in the market, consumers have more options for supply of necessary products.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-15111

This scenario promotes market competition, thus, key companies typically use high-impact marketing campaigns and launch test kits with variety of innovation to attract customers. For instance:

• In May 2022, Thermo Fisher Scientific and LabShares partnered to support the emerging Boston biotech ecosystem. This will help validate and commercialize the next generation of life-saving therapies, including the biotech and life science segments.
• In May 2022, Babson and BD expanded their strategic partnership to advance diagnostic blood collection that will allow to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.
• In December 2021, PerkinElmer launched NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to strengthen SARS-CoV-2 surveillance.
• In April 2022, Abbott had overall 12 COVID testing solutions like BinaxNOW COVID-19 Antigen Self-Test and Panbio COVID-19 Antigen Self-Test. It also took the initiative of the Pandemic Defense Coalition, the first-ever industry-led scientific and global health partnership dedicated to the early detection of and rapid response to future pandemic threats.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the coronavirus immunoassay market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (immunoassay kits & reagents [kits, primary antibodies, secondary antibodies, immunoassay substrates, immunoassay buffers], analysers & instruments, consumables, and software), by assay (ELISA, FIA, CLIA, LFA, and others), by purpose (research use only, and clinical use), by specimen (blood, saliva, nasopharynx, and cell culture samples), by application (clinical diagnostics, drug discovery, and screening of diseases & disorders), by end user (healthcare industry, [human use, and veterinary]), across seven key regions of the world.

Key Market Segments Covered in Coronavirus Immunoassay Industry Research

By Product:

• Immunoassay Kits & Reagents
  • Kits
  • Primary Antibodies
  • Secondary antibodies
  • Immunoassay Substrates
  • Immunoassay Buffers
• Analysers & Instrument
• Consumables
• Software

By Assay:

• ELISA
• FIA
• CLIA
• LFA
• Others

By Purpose:

• Research Use Only
• Clinical Use

By Specimen:

• Blood
• Saliva
• Nasopharynx
• Cell Culture Samples

By Application:

• Clinical Diagnostics
• Drug Discovery
• Screening of diseases & disorders

By End User:

• Healthcare Industry
  • Human Use
  • Veterinary

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-15111

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions & Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Disease Epidemiology

4.2. Key Strategies, by Market Players

4.3. Technological Advancements

4.4. New Product launches & Approvals

4.5. Regulatory landscape

4.6. Reimbursement Scenario

4.7. Value Chain Analysis

4.8. Product Adoption Analysis

4.9. PESTLE Analysis

4.10. Porter’s Analysis

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-15111

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Global Heart Block Therapeutics Market was valued at US$ 3 Bn in 2021 and is expected to reach US$ 4.8 Bn by 2032, find Future Market Insights (FMI) in a recent market survey. As per the findings of the report, Pacemakers, among all products will garner significant demand in the market as the bulk of revenue will be generated through them. Revenue through pacemakers grew at a CAGR of 4.8% during 2015 – 2021.

Older Populace Swells Worldwide, Propels the Global Demand for Heart Block Therapeutics

According to the United Nations Department of Economic and Social Affairs, by 2050, the population of 60 years old and above is expected to reach 437 Mn in China, 324 Mn in India, 107 Mn in The US, and 58 Mn in Brazil. Hence, the growing older populace propels the worldwide Heart Block Therapeutics market as the older population is more prone to heart-related diseases. The World Health Organization (WHO) reported that around 524 Mn people represent the geriatric population in 2010 and by 2050, almost 2 Bn people will be geriatric.

The US Continues Being the Largest Revenue Stream for Heart Block Therapeutics Market

Heart Block Therapeutics market in the US to reach a valuation of US$ 1.7 Bn   by 2032. From 2015 to 2021, the market revenue through the US grew at a CAGR of 4.7%, while between 2022 and 2032, it is predicted to witness a CAGR of 4.1%. The combination of innovative treatment technology, adoption of digital solutions, and shifting provider and care delivery shifts provides the Heart Block Therapeutics Industry with tremendous growth potential in the United States. Between 2022 and 2032, the US is expected to be a market with a US$ 570.5 Mn absolute dollar opportunity.

“Introduction of artificial intelligence technology in the Heart Blockage surgeries will be the biggest step towards increasing the revenue growth of Heart Block Therapeutics Market” comments an analyst at Future Market Insights.

Heart Block Therapeutics Market: Competition Insights

The key companies dominating the Heart Block Therapeutics Market are St. Jude Medical, Medtronic, Bristol Myers Squibb, Novartis AG, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Edward Lifesciences Corporation, Abbott Laboratories, Natco Pharma, Pfizer Inc., Bayer AG, Astra Zeneca, Sanofi, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-15097

Some of the recent developments by the key providers of Heart Block Therapeutics are as follows: 

• In April 2022, Bristol Myers Squibb announced that they have received approval from US Food and Drug Corporation for its oral heart disease drug Mavacamten which will help in treating hypertrophic cardiomyopathy, a genetic heart disease that leads to sudden cardiac arrests in young people.
• In June 2020, Edward Lifesciences Corporation (USA) confirmed that they have received Chinese approval for the SAPIEN 3 Trans catheter heart valve for the treatment of patients with severe and symptomatic aortic stenosis (AS) who are not able to undergo open-heart surgery.
• In September 2019, Medtronic (USA) Received US Food and Drug Corporation clearance for its Next Generation Evolut PRO+ TAVR System for the Treatment of Symptomatic Severe Aortic Stenosis in Patients. The Evolut PRO+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest indicated patient treatment range and the lowest delivery profile currently on the market.
• In March 2019, Abbott (USA) Received US Food and Drug Corporation Clearance Anthos Therapeutics for Cardiovascular Drug Development which focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.

• In February 2019, Novartis AG and Blackstone’s Life sciences announced the launch of Anthos Therapeutics for the development of cardiovascular drugs. As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway.
• In January 2019, India-based Natco Pharma announced the launch of valsartan sacubitril, a cardiovascular drug that is used to treat congestive heart failure in patients.

Key Segments Covered in Heart Block Therapeutics Market Survey

By Type:

• First Degree Heart Blocks
• Second Degree Heart Blocks
• Third Degree Heart Blocks

By Product:

• Transcutaneous pacing (TCP)
• Pacemaker
• Mediation
• Follow-up electrophysiology study

By End User:

• Hospital Testing
• Home Treatment
• Clinics
• Others

By Region:

• North America
• Europe
• APAC
• MEA
• Latin America

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-15097

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Summary of Statistics

1.3. Key Market Characteristics & Attributes

1.4. FMI Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

3.1. Risk Assessment

3.1.1. COVID-19 Crisis and Impact on Heart Block Therapeutics

3.1.2. COVID-19 Impact Benchmark with Previous Crisis

3.1.3. Impact on Market Value (US$ Mn)

3.1.4. Assessment by Key Countries

3.1.5. Assessment by Key Market Segments

3.1.6. Action Points and Recommendation for Suppliers

3.2. Key Trends Impacting the Market

3.3. Formulation and Product Development Trends

4. Market Background

4.1. Heart Block Therapeutics Market, by Key Countries

4.2. Heart Block Therapeutics Market Opportunity Assessment (US$ Mn)

4.2.1. Total Available Market

4.2.2. Serviceable Addressable Market

4.2.3. Serviceable Obtainable Market

4.3. Market Scenario Forecast

4.3.1. Demand in optimistic Scenario

4.3.2. Demand in Likely Scenario

4.3.3. Demand in Conservative Scenario

4.4. Investment Feasibility Analysis

4.4.1. Investment in Established Markets

4.4.1.1. In Short Term

4.4.1.2. In Long Term

4.4.2. Investment in Emerging Markets

4.4.2.1. In Short Term

4.4.2.2. In Long Term

4.5. Forecast Factors – Relevance & Impact

4.5.1. Top Companies Historical Growth

4.5.2. Growth in Automation, By Country

4.5.3. Patch  Management Adoption Rate, By Country

4.6. Market Dynamics

4.6.1. Market Driving Factors and Impact Assessment

4.6.2. Prominent Market Challenges and Impact Assessment

4.6.3. Patch  Management Market Opportunities

4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

5.2. Banking on with Segments High Incremental Opportunity

5.3. Peer Benchmarking

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The critical care patient monitoring products market is expected to grow at a CAGR of 8.6%. The introduction of remote monitoring systems, mobile cardiac telemetry devices, mobile personal digital assistant (PDA) systems, ambulatory wireless EEG recorders, and ambulatory event monitors are significant drivers boosting the critical care patient monitoring products market’s growth. Critical care units are special departments of health care facilities that caters to critically ill patients or those with life threatening severe illnesses. Thus, critical care units can be defined as the area of health care facility which is equipped with special resuscitation as well a monitoring equipment that are essential in order to address critical emergencies. The critical care unit necessitates close monitoring and support by means of specialist equipment which ensure normal functioning of the various organs of the body. The various equipment that serve the function of monitoring and addressing critical conditions of patients comprise hemodynamic monitoring products, vital signs monitoring products, neurologic monitoring systems among the others.

Critical Care Patient Monitoring Products Market: Drivers & Restraints

The global critical Care Patient Monitoring Products market is expected to witness a steady growth during the forecast period. The growth of overall health care sector during the forecast period is expected to influence the growth of global critical care patient monitoring products market. Besides this, the major driving factors for global critical care patient monitoring products market are population aging and an increase in rate of chronic diseases. Moreover, increase in number of health care facilities across the globe is expected to fuel the growth of global critical care patient monitoring products. Also, Increase in lifestyle influenced diseases such as coronary heart diseases, along with the growing affluence has resulted in a steady growth in demand for critical care patient monitoring products. On the flip side, the high cost of these critical care products can act as an impediment to the growth of global critical care patient monitoring products market.

On the basis of geographic regions of the globe, global Critical Care Patient Monitoring Products market is segmented into seven major segments. These key market segments are North America, Western Europe, Eastern Europe, Asia Pacific, Japan, and Middle East & Africa, Latin America.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-575

Region-wise Outlook of the Critical Care Patient Monitoring Products Market:

On the basis of geographic regions of the globe, global Critical Care Patient Monitoring Products market is segmented into seven major segments. These key market segments are North America, Western Europe, Eastern Europe, Asia Pacific, Japan, and Middle East & Africa, Latin America.

Competitive Outlook for the Critical Care Patient Monitoring Products Market:

Medtronic plc is a global leader in critical care patient monitoring products. In the critical care patient monitoring products market, Medtronic plc (US) offers a wide range of products, including neuromonitoring, respiratory monitoring devices, cardiac monitoring devices, and blood glucose monitoring devices.

BIS, the brain monitoring system, is the company’s flagship product and one of the most extensively utilised systems in the critical care patient monitoring products market. With increased investment in its R&D department, the firm is focusing on innovations and enhancing the quality of its products. Medtronic’s global reach allows it to serve sales of critical care patient monitoring products customers from more than 150 countries, including Germany, the United Kingdom, New Zealand, Australia, and the United States

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-575

 Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. Value Chain Analysis

3.5.1. Profit Margin Analysis

3.5.2. Service Providers

3.6. PESTLE and Porter’s Analysis

3.7. Regulatory Landscape

3.7.1. By Key Regions

3.7.2. By Key Countries

3.8. Regional Parent Market Outlook

4. Global Critical Care Patient Monitoring Products Market Analysis 2017-2021 and Forecast, 2022-2032

4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-575

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs